JP2019516663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516663A5 JP2019516663A5 JP2018543337A JP2018543337A JP2019516663A5 JP 2019516663 A5 JP2019516663 A5 JP 2019516663A5 JP 2018543337 A JP2018543337 A JP 2018543337A JP 2018543337 A JP2018543337 A JP 2018543337A JP 2019516663 A5 JP2019516663 A5 JP 2019516663A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- fragment
- cancer
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 239000012634 fragment Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086571A JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
| JP2022206084A JP7564183B2 (ja) | 2016-03-01 | 2022-12-22 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
| JP2024167901A JP2025011134A (ja) | 2016-03-01 | 2024-09-26 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302010P | 2016-03-01 | 2016-03-01 | |
| GBGB1603568.5A GB201603568D0 (en) | 2016-03-01 | 2016-03-01 | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB1603568.5 | 2016-03-01 | ||
| US62/302,010 | 2016-03-01 | ||
| PCT/EP2017/054559 WO2017148888A1 (en) | 2016-03-01 | 2017-02-28 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086571A Division JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516663A JP2019516663A (ja) | 2019-06-20 |
| JP2019516663A5 true JP2019516663A5 (cg-RX-API-DMAC7.html) | 2020-04-09 |
Family
ID=55807140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543337A Pending JP2019516663A (ja) | 2016-03-01 | 2017-02-28 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
| JP2021086571A Active JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086571A Active JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Country Status (18)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173560A1 (en) | 2020-02-24 | 2021-09-02 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| MA54832A (fr) | 2016-03-01 | 2021-12-01 | Immatics Biotechnologies Gmbh | Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| US11111277B2 (en) | 2016-12-28 | 2021-09-07 | Invvax, Inc. | Influenza vaccines |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| US20190016804A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| CA3083242A1 (en) * | 2017-11-21 | 2019-05-31 | Naofumi MIWA | Human cancer cell metastasis inhibitory agent and human cancer cell determination agent |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2019204683A1 (en) * | 2018-04-19 | 2019-10-24 | Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| JP7534962B2 (ja) | 2018-06-19 | 2024-08-15 | ビオンテック ユーエス インコーポレイテッド | ネオ抗原およびその使用 |
| CN109801270B (zh) | 2018-12-29 | 2021-07-16 | 北京市商汤科技开发有限公司 | 锚点确定方法及装置、电子设备和存储介质 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| JP2022536695A (ja) * | 2019-06-12 | 2022-08-18 | ビオンテック ユーエス インコーポレイテッド | 新抗原組成物およびその使用 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN111118011B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN116024176A (zh) * | 2020-07-14 | 2023-04-28 | 广州泛恩生物科技有限公司 | 基于tnfrsf18阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| MX2023007817A (es) | 2020-12-31 | 2023-09-13 | Immatics Us Inc | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| US12319720B2 (en) * | 2021-08-31 | 2025-06-03 | Washington University | Neoantigen vaccines for triple negative breast cancer |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| EP4514829A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115785206B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标07及其用途 |
| CN115961032A (zh) * | 2022-09-19 | 2023-04-14 | 深圳市罗湖区人民医院 | 一种膀胱癌相关突变基因的检测探针、检测试剂盒、突变质控品 |
| WO2025021968A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Antigen binding proteins against mageb2 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1463928A2 (en) * | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| AU2003253632A1 (en) | 2002-06-10 | 2003-12-22 | Idec Pharmaceuticals Corporation | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| SI1806359T1 (sl) * | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
| KR100906145B1 (ko) * | 2006-05-30 | 2009-07-03 | 한국생명공학연구원 | Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제 |
| KR20140072201A (ko) * | 2006-07-05 | 2014-06-12 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제 |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| EP2336771A1 (en) * | 2009-12-16 | 2011-06-22 | Universität Duisburg-Essen | HAS3v2 as tumor marker |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201511792D0 (en) * | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
-
2016
- 2016-03-01 GB GBGB1603568.5A patent/GB201603568D0/en not_active Ceased
-
2017
- 2017-02-28 US US15/445,461 patent/US10400011B2/en active Active
- 2017-02-28 EP EP21171324.3A patent/EP3915577A1/en active Pending
- 2017-02-28 CR CR20210033A patent/CR20210033A/es unknown
- 2017-02-28 BR BR112018016734A patent/BR112018016734A2/pt not_active Application Discontinuation
- 2017-02-28 MX MX2018010167A patent/MX2018010167A/es unknown
- 2017-02-28 KR KR1020187027578A patent/KR20180118702A/ko not_active Ceased
- 2017-02-28 AU AU2017227967A patent/AU2017227967B2/en not_active Expired - Fee Related
- 2017-02-28 MA MA043690A patent/MA43690A/fr unknown
- 2017-02-28 EP EP17707843.3A patent/EP3423085A1/en not_active Withdrawn
- 2017-02-28 CN CN201780014493.6A patent/CN109152825A/zh active Pending
- 2017-02-28 MA MA43090A patent/MA43090A1/fr unknown
- 2017-02-28 JP JP2018543337A patent/JP2019516663A/ja active Pending
- 2017-02-28 SG SG10202110228Y patent/SG10202110228YA/en unknown
- 2017-02-28 SG SG10202008107QA patent/SG10202008107QA/en unknown
- 2017-02-28 CA CA3014848A patent/CA3014848A1/en active Pending
- 2017-02-28 SG SG11201806951TA patent/SG11201806951TA/en unknown
- 2017-02-28 CR CR20210034A patent/CR20210034A/es unknown
- 2017-02-28 CR CR20180398A patent/CR20180398A/es unknown
- 2017-02-28 EA EA201891670A patent/EA201891670A1/ru unknown
- 2017-02-28 CR CR20210035A patent/CR20210035A/es unknown
- 2017-02-28 IL IL261266A patent/IL261266B2/en unknown
- 2017-02-28 WO PCT/EP2017/054559 patent/WO2017148888A1/en not_active Ceased
- 2017-03-01 TW TW106106638A patent/TWI641617B/zh not_active IP Right Cessation
-
2018
- 2018-08-22 CO CONC2018/0008763A patent/CO2018008763A2/es unknown
-
2021
- 2021-05-23 JP JP2021086571A patent/JP7201740B2/ja active Active
- 2021-06-22 AU AU2021204201A patent/AU2021204201B2/en not_active Ceased